Secretory factors produced by adipose mesenchymal stem cells downregulate Th17 and increase Treg cells in peripheral blood mononuclear cells from rheumatoid arthritis patients
- 31 Downloads
We aimed to assess the immunoregulatory effects of secretory factors produced by adipose tissue-derived MSC (AT-MSC) on Th17 and Treg subsets from patients with rheumatoid arthritis (RA). 17 patients with active disease matching the ACR/EULAR 2010 criteria for RA were included. Patients’ peripheral blood mononuclear cells (PBMC) were cultured in AT-MSC-conditioned medium (AT-MSCcm) and in control medium. The cytokine production of AT-MSC and PBMC was quantified by ELISA. Th17 and Treg were determined by flow cytometry. AT-MSCcm contained: IL-6, IL-17, IL-21, CCL2, CCL5, IL-8, sVEGF-A and PGE2. Cultivation of patients’ PBMC with AT-MSCcm increased TGF-β1 (8318 pg/ml; IQR 6327–11,686) vs control medium [6227 pg/ml (IQR 1681–10,148, p = 0.013)]. PBMC cultivated with AT-MSCcm downregulated TNF-α, IL-17A, and IL-21 compared to control PBMC: 5 pg/ml IQR (1.75–11.65) vs 1 pg/ml (IQR 0.7–1.9), p = 0.001; 4.2 pg/ml (IQR 3.1–6.1) vs 2.3 pg/ml (IQR.75–5.42), p = 0.017; 66.9 pg/ml (IQR 40.6–107.2) vs 53 pg/ml (IQR 22–73), p = 0.022. Th17 decreased under the influence of AT-MSCcm: 10.13 ± 3.88% vs 8.98 ± 3.58%, p = 0.02. CD4+FoxP3+, CD4+CD25−FoxP3+, and CD4+CD25+FoxP3+ was 11.35 ± 4.1%; 7.13 ± 3.12% and 4.22 ± 2% in control PBMC. Accordingly, CD4+FoxP3+, CD4+CD25−FoxP3+, and CD4+CD25+FoxP3+ significantly increased in PBMC cultured with AT-MSCcm: 15.6 ± 6.1%, p = 0.001; 9.56 ± 5.4%, p = 0.004 and 6.04 ± 3.6%, p = 0.001. All these effects could define MSC-based approaches as adequate avenues for further treatment development in RA.
KeywordsMesenchymal stem cells Immunosuppression Rheumatoid arthritis Th17 Treg Cytokines
Research concept and design: DK. Methodology: EI-T, MI. Data curation: GV. Investigation: GV, EK, KY, MI, RS. Data analysis and interpretation: DK, GV. Project administration: GV. Validation: DK. Writing the article: GV. Critical revision and editing of the article: DK, MI, EI-T, EK.
This work is a part of the doctoral thesis of Georgi Vasilev MD and was supported by Medical University of Sofia under the project ‘Young Investigator’ No: 7679/21.11.19, contract No: 128/2018.
Compliance with ethical standards
Conflict of interest
Authors report no conflict of interest concerning this article.
All experiments performed in this study involving human participants were approved by the institutional and national research committee and complied with the Helsinki Declaration of 1964 and its later amendments (2008).
Voluntarily signed informed consent was obtained from all participants in accordance with the ethical recommendations of the Helsinki Declaration before entering the study.
- 3.Pittenger MF, Mosca JD, McIntosh KR (2000) Human mesenchymal stem cells: progenitor cells for cartilage, bone, fat and stroma. In: Melcher F (ed) Lymphoid organogenesis. Current topics in microbiology and immunology, vol 251. Springer, Berlin. https://doi.org/10.1007/978-3-642-57276-0_1 Google Scholar
- 7.Álvaro-Gracia JM, Jover JA, García-Vicuña R et al (2017) Intravenous administration of expanded allogeneic adipose-derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial. Ann Rheum Dis 76:196–202. https://doi.org/10.1136/annrheumdis-2015-208918 CrossRefGoogle Scholar
- 9.Karussis D, Kassis I, Kurkalli BG, Slavin S (2008) Immunomodulation and neuroprotection with mesenchymal bone marrow stem cells (MSCs): a proposed treatment for multiple sclerosis and other neuroimmunological/neurodegenerative diseases. J Neurol Sci 265:131–135. https://doi.org/10.1016/j.jns.2007.05.005 CrossRefGoogle Scholar
- 10.Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O (2008) Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579–1586. https://doi.org/10.1016/S0140-6736(08)60690-X CrossRefGoogle Scholar
- 13.Ivanova-Todorova E, Bochev I, Dimitrov R, Belemezova K, Mourdjeva M, Kyurkchiev S, Kinov P, Altankova I, Kyurkchiev D (2012) Conditioned medium from adipose tissue-derived mesenchymal stem cells induces CD4+FOXP3+ cells and increases IL-10 secretion. J Biomed Biotechnol 2012:295167. https://doi.org/10.1155/2012/295167 CrossRefGoogle Scholar
- 16.NajarM Rouas R, Raicevic G, Boufker HI, Lewalle P, Meuleman N et al (2009) Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 11:570–583. https://doi.org/10.1080/14653240903079377 CrossRefGoogle Scholar
- 20.Kim HS, Shin TH, Lee BC, Yu KR, Seo Y, Lee S, Seo MS, Hong IS, Choi SW, Seo KW, Nunez G, Park JH, Kang KS (2013) Human umbilical cord blood mesenchymal stem cells reduce colitis in mice by activating NOD2 signaling to COX2. Gastroenterology 145(1392–1403):e1–e8. https://doi.org/10.1053/j.gastro.2013.08.033 Google Scholar
- 21.Tanaka H, Arimura Y, Yabana T, Goto A, Hosokawa M, Nagaishi K, Yamashita K, Yamamoto H, Sasaki Y, Fujimiya M, Imai K, Shinomura Y (2011) Myogenic lineage differentiated mesenchymal stem cells enhance recovery from dextran sulfate sodium-induced colitis in the rat. J Gastroenterol 46:143–152. https://doi.org/10.1007/s00535-010-0320-7 CrossRefGoogle Scholar
- 27.Rafei M, Hsieh J, Fortier S, Li M, Yuan S, Birman E, Forner K, Boivin MN, Doody K, Tremblay M, Annabi B, Galipeau J (2008) Mesenchymal stromal cell-derived CCL2 suppresses plasma cell immunoglobulin production via STAT3 inactivation and PAX5 induction. Blood 112:4991–4998. https://doi.org/10.1182/blood-2008-07-166892 CrossRefGoogle Scholar
- 33.Bianchini R, Bistoni O, Alunno A, Petrillo MG, Ronchetti S, Sportoletti P, Bocci EB, Nocentini G, Gerli R, Riccardi C (2011) CD4+CD25lowGITR+ cells: a novel human CD4+ T-cell population with regulatory activity. Eur J Immunol 41:2269–2278. https://doi.org/10.1002/eji.201040943 CrossRefGoogle Scholar